Sanofi and Verily launch diabetes management platform
In a joint venture, Sanofi and Verily are launching a diabetes management platform that will provide tools and technology to aid in improving daily life for patients, according to a press release from the companies.
The platform, called Onduo, will incorporate the expertise of Verily — a unit of Google parent, Alphabet — in miniaturized electronics, analytics and software with Sanofi’s focus on medicine and new therapies in order to help diabetes patients make better decisions and improve habits and outcomes. It is being developed with input from diabetes patients, clinicians, payers and health care professionals.
“From monitoring food intake to testing glucose levels to actively seeking medical care, the challenges both on the physical and mental well-being of a person living with diabetes are incredibly difficult,” Joshua Riff, MD, MBA, CEO of Onduo, said in the release. “We want to develop solutions that allow people living with diabetes to focus on the things they love and enjoy in life by providing tools to make dealing with their diabetes less burdensome.”
Onduo is launching with the type 2 diabetes community, but Sanofi and Verily hope to expand this to those with type 1 and prediabetes eventually.
“This is an innovative collaboration that spans the health care continuum and benefits from deep and cross-functional expertise, giving us unique potential to create tools and solutions that could have a positive clinical effect,” Jessica Mega, MD, MPH, chief medical officer of Verily, said in the release. “Our goal is to connect the dots for health care providers on the 'moments of truth' that happen outside of the clinical setting, and to help people manage diabetes on a daily basis.”